PharmaLectures.com

Courses › Pharma industry foundations › Is it a drug or a device: combination products and when MDR takes over

Is it a drug or a device: combination products and when MDR takes over

Your team settles drug or device before the dossier, and the deal keeps its date.

The EU MDR is Regulation (EU) 2017/745 on medical devices, which has applied since 26 May 2021. For a drug and device combination, the deciding question is the principal intended action. If the device part delivers a medicine and forms a single integral product, it is regulated as a medicine under Directive 2001/83/EC, but the device part must still meet the MDR general safety and performance requirements, often shown by a notified body opinion. If the medicine only supports the device, the MDR applies. This course shows teams how to classify correctly.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, BDwho it is written for

Why EU MDR training matters

A reviewer sends back your combination product dossier because the principal intended action is wrong. Regulatory Affairs rewrites the strategy, and business development tells the partner the launch date has moved. The deal talks go quiet.

What changes after this course

Your team names the principal intended action and picks medicinal product law or the Medical Device Regulation before development starts. Classification arguments end with a documented answer. You hold a certificate per learner and a training record for every person, ready for any auditor.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

EU MDR training: what this course gives your people

Your Regulatory Affairs manager no longer waits for a legal opinion to say whether a new project is a device or a drug-device combination. They read Article 1(8) and Article 1(9) of the Medical Device Regulation against the product, name the principal intended action in the kick-off meeting, and draft the first submission under the right regime. Development scientists stop reworking designs late.

A borderline product no longer turns into a standoff between departments. When quality, development and regulatory disagree, your staff open the Medical Device Coordination Group guidance MDCG 2022-5, find the example closest to the product and cite it. The decision is written down once, with its source, and nobody reopens it at the next meeting.

Business development gets a straight answer instead of a maybe. Because the pathway is fixed from day one, either medicinal product law under Directive 2001/83/EC or the Medical Device Regulation, the person valuing a partnership can put a realistic market entry date in the model and defend it when the partner pushes back.

Conformity assessment stops being a last-minute scramble. Your team knows when the Notified Body must see the device part, what the CE marking route asks for, and how to answer an inspector who opens Article 1 of the Medical Device Regulation and asks why this product sits where it does.

Who needs EU MDR training

  • Regulatory Affairs Manager

    Your team has spent two weeks arguing the principal intended action for a new combination product while the dossier sits unwritten. You need one documented answer before the strategy document is rewritten again.

  • Business Development Lead

    You are valuing a partnership and the launch date depends on a classification nobody has confirmed. You need the conformity assessment steps in hand before the term sheet goes out.

  • Product Development Scientist

    You are designing the device component of a delivery system and nobody has said whether the Medical Device Regulation applies. You need the answer before prototype work is built on the wrong assumption.

  • Quality Assurance Specialist

    An auditor asks for the rationale behind a combination product's classification. You need a file ready that shows the Medical Device Coordination Group guidance 2022-5 was applied to the borderline call.

Roles: Business development and export sales, Regulatory affairs

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: any jurisdiction

Courses are in English. Other languages on request.

After this course your people can

  1. Sort a new product into medical device or drug-device combination product and state the legal reason in writing.
  2. Name the principal intended action of a combination product and set the regulatory pathway that follows from it.
  3. Apply Article 1 of the Medical Device Regulation to a product and record whether the regulation covers it.
  4. Find the closest example in Medical Device Coordination Group guidance 2022-5 for a borderline product and cite it in your rationale.
  5. Map the CE marking route for stand-alone devices and the notified body opinion for the device part of integral products.
  6. Give business development a classification summary and a conformity assessment timeline they can use in a partnership forecast.

What the company gets

  • Early combination products enter the right regulatory pathway on day one, so the first dossier is written once.
  • The risk of a returned submission over a wrong principal intended action drops, because the call is made and documented before drafting starts.
  • Business development negotiates with a conformity assessment and Notified Body timeline it can defend to a partner.
  • Inspectors receive a written rationale, based on Medical Device Coordination Group guidance 2022-5, for each borderline classification decision.
  • Each learner holds a certificate and each person has a training record, so competence is shown with documents, not claims.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing1 h
Regulatory affairsStandard2 h 30 min

EU MDR course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Tell a medical device from a drug-device combination product on sight

    • How to spot the device hiding inside a drug project before anyone drafts a submission.
    • Why Article 1(8) and 1(9) of the Medical Device Regulation send similar products down different roads.
    • What a wrong filing costs you: deficiency questions, a forced pathway change or a refusal.
  2. 2Name the principal intended action for any drug-device combination

    • The rule that names your principal intended action, so the pathway is fixed before kick-off.
    • What to do when two active components both claim the principal intended action.
    • How to write the rationale once so Regulatory Affairs, development and quality sign the same page.
  3. 3Decide whether the Medical Device Regulation (MDR) covers your product

    • How to read Article 1 of the Medical Device Regulation and write down why it does or does not apply.
    • Where Annex VIII classification rules come in, so your device class rests on a written rule, not a hunch.
    • What to say when an auditor finds an MDR-covered product that your classification process let through.
  4. 4Settle borderline cases with Medical Device Coordination Group 2022-5

    • How to end a borderline argument between departments by pointing to a page in MDCG 2022-5.
    • The worked examples in the guidance that sit closest to your product, and how to cite them.
    • Why a borderline call made without the guidance invites different demands from different reviewers.
  5. 5Plan the CE marking route and Notified Body steps for the device part

    • When to bring a Notified Body in, and when waiting costs you the launch date.
    • The sequence of steps that proves the device part of your combination product conforms.
    • What a late first call to a Notified Body does to your launch date and your investor update.
  6. 6Shape business development deals around the right regulatory pathway

    • How to give business development a classification summary that backs a launch forecast.
    • What to ask for in the first partner call so the regulatory pathway sits in the term sheet.
    • Why a misclassified product turns into re-submissions and a partner who stops returning calls.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about EU MDR training

When does the EU MDR apply instead of medicines law?

The MDR applies when the product achieves its principal intended action by physical means, such as a barrier or mechanical action, rather than by pharmacological, immunological or metabolic means. If a medicinal substance in the device only has an action ancillary to the device, the product stays under the MDR, and a medicines authority is consulted on the substance. MDCG 2022-5 gives guidance on borderline cases.

What is a notified body opinion for a drug-device combination?

Article 117 of the MDR amended Directive 2001/83/EC so that a marketing authorisation application for an integral drug-device product must include evidence that the device part meets the MDR general safety and performance requirements. Where the device part on its own would need a notified body, the applicant usually provides a notified body opinion. Without it, the application may lack the required evidence that the device part meets the MDR requirements.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team